This upside was driven by solid sales growth of the asthma inhaler Trelegy Ellipta across all regions, reflecting patient demand. The adverse impact of removing the Average Manufacturer Price (AMP ...

Amanda Southcombe, GSK NZ general manager, says funding for Trelegy Ellipta was recently announced, a single inhaler triple-therapy to treat the disease, which will see around 15,000 Kiwis ...

Amanda Southcombe, GSK NZ General Manager, says funding for Trelegy Ellipta was recently announced, a single inhaler triple-therapy to treat the disease, which will see around 15,000 Kiwis ...

We need better utilisation of funding, more clinicians, and greater access to diagnostics,” he said. Amanda Southcombe, General Manager of GSK NZ, said recent funding for Trelegy Ellipta, a ...

Amanda Southcombe, GSK NZ General Manager, says funding for Trelegy Ellipta was recently announced, a single inhaler triple-therapy to treat the disease, which will see around 15,000 Kiwis suffering ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler that’s prescribed for COPD. This article covers topics such as side effects, dosage ...

Meanwhile GSK's lead inhalers include Trelegy Ellipta, projected to bring $3.3bn in 2024 sales, followed by Relvar/Breo Ellipta and Seretide/Advair GlobalData is the patent company of ...

Meanwhile GSK's lead inhalers include Trelegy Ellipta, projected to bring $3.3bn in 2024 sales, followed by Relvar/Breo Ellipta and Seretide/Advair GlobalData is the patent company of Pharmaceutical ...

Trelegy Ellipta is a once-daily, single inhaler triple therapy from GSK, in collaboration with Innoviva, approved as a long-term maintenance treatment for certain patients with chronic obstructive ...

Stock score of GlaxoSmithKline Pharmaceuticals Ltd moved up by 1 in a month on a 10 point scale (Source: Refinitiv). Get detailed report on GlaxoSmithKline Pharmaceuticals Ltd by subscribing to ...